key: cord-0932387-5zjflfum
authors: Zhang, Ling; Cai, Hong; Bai, Wei; Zou, Si-Yun; Feng, Ke-Xin; Li, Yu-Chen; Liu, Huan-Zhong; Du, Xiangdong; Zeng, Zhen-Tao; Lu, Chang-Mou; Zhang, Lan; Mi, Wen-Fang; Ding, Yan-Hong; Yang, Juan-Juan; Jackson, Todd; Cheung, Teris; Su, Zhaohui; An, Feng-Rong; Xiang, Yu-Tao
title: Prevalence of suicidality in clinically stable patients with the major depressive disorder during the COVID-19 pandemic
date: 2022-03-22
journal: J Affect Disord
DOI: 10.1016/j.jad.2022.03.042
sha: 5ad53263bc17d4c54dd0b72012a93184016d5cff
doc_id: 932387
cord_uid: 5zjflfum

BACKGROUND: The COVID-19 pandemic is associated with an increased risk of mental health problems including suicide in many subpopulations, but its influence on stable patients with major depressive disorder (MDD) has been studied fleetingly. This study examined the one-year prevalence of suicidality including suicidal ideation (SI), suicide plans (SP), and suicide attempts (SA) as well as their correlates in clinically stable MDD patients during the COVID-19 pandemic. METHODS: A cross-sectional, observational study was conducted between October 1, 2020, and October 15, 2021 in six tertiary psychiatric hospitals. Socio-demographic information, clinical data and one-year prevalence of suicidality were recorded. RESULTS: Altogether, 1718 participants who met the eligibility criteria were included. The overall one-year prevalence of suicidality during the COVID-19 pandemic was 68.04% (95% confidence intervals (CI) =65.84–70.25%), with one-year SI prevalence of 66.4% (95%CI = 64.18%–68.65%), SP prevalence of 36.26% (95%CI = 33.99%–38.54%), and SA prevalence of 39.35% (95%CI = 37.04%–41.66%). Binary logistic regression analyses revealed male gender, married marital status, college education level and above and age were negatively associated with risk of suicidality. Urban residence, unemployed work status, experiences of cyberbullying, a history of suicide among family members or friends, and more severe fatigue, physical pain, and residual depressive symptoms were positively associated with risk of suicidality. CONCLUSIONS: Suicidality is common among clinically stable MDD patients during the COVID-19 pandemic. Regular suicide screening and preventive measures on suicide should be provided to clinically stable MDD patients during the pandemic.

Suicide is a major global public health challenge. The WHO estimated that the global suicide rate is around 10.6 per 100,000 population (7.7 for females and 13.5 for males) (World Health Organization, 2020) . Suicidality reflects a continuum that includes suicidal ideation (SI), suicide plans (SP), suicide attempts (SA) and suicide. SI, SP, and SA, respectively, refer to thoughts or wishes about ending one"s life, making plans to end one"s life, and self-destructive actions with at least some intent to end one"s own life (Kao et al., 2012; Posner, 2007) . Compared to other psychiatric disorders, major depressive disorder (MDD) is more likely to cause suicidality (Hawton et al., 2013) .

Approximately 90% of suicide victims suffer from one or more mental illnesses (Cavanagh, 2003; Nordentoft, 2011) , with MDD alone accounting for 59-87% of all suicides (Cavanagh, 2003; Nordentoft, 2011) . A meta-analysis revealed that global prevalence rates of SI, SP and SA among MDD patients are 37.7% (95% CI = 32. The COVID-19 pandemic itself and related negative outcomes such as social isolation and economic recession are associated with increased likelihood of mental health problems (Zhao et al., 2021) that may increase risk of suicidality (Reger et al., 2020; Sinyor et al., 2021) . Previous studies have found that the overall prevalence of SI is 16.4% in the general population of China during the COVID-19 pandemic (Shi et al., 2021) . Moreover, 19.2% of veterans with pre-existing psychiatric conditions in the US screened positive for SI during the peri-pandemic period (Na et al., 2021) . A multivariable analysis has also linked greater pre-pandemic psychiatric symptom severity, past-year SI, lifetime SA, psychosocial difficulties, COVID-19 infection, and past-year increases in psychiatric symptom severity to peri-pandemic SI (Na et al., 2021) . In addition, individuals with psychiatric disorders have a 1.64-fold higher risk of SI compared to those without disorders (Papadopoulou et al., 2021) .

One limitation of the literature on suicidality during the COVID-19 pandemic is that studies have tended to focus exclusively upon SI (Na et al., 2021; Shi et al., 2021) , even though suicidality also comprises SP and SA (Tuisku et al., 2006) .

In addition, studies have tended to assess risk in heterogeneous populations so less in known about prevalence and predictors within certain diagnostic groups such as people with MDD. Although evaluating suicidality is an integral part of suicide risk assessment and prevention for patients with MDD, we could not identify studies that considered prevalence of SI, SP and SA in MDD patients during the COVID-19 pandemic, particularly among those who are clinically stable and account for the majority of this population. To reduce the risk of future suicide in patients with MDD, it is important to document the pattern of suicidality and its correlates in a more comprehensive manner.

In this study, we examined the one-year prevalence of SI, SP and SA in clinically stable MDD patients during the COVID-19 pandemic as well as sociodemographic, psychiatric, and well-being correlates of suicidality in this population. We hypothesized that SI, SP and SA in clinically stable MDD patients during the COVID-19 pandemic would be more common compared to the corresponding figures documented in this subpopulation prior to the pandemic.

This was a cross-sectional, observational study conducted between October 1, 2020 and October 15, 2021 in six tertiary psychiatric hospitals distributed in east, west, south, and north regions of China (i.e., Beijing, Guangxi, Jiangsu, Fujian, Gansu, and Anhui). All patients who attended outpatient and inpatient services in participating psychiatric hospitals during the study period were consecutively invited to participate in this study. Patients were invited to scan a Quick Response code (QR Code) linked to the study introduction and invitation with their own or a guardian"s smartphone. After providing electronic written informed consent, J o u r n a l P r e -p r o o f Journal Pre-proof patients could access the data collection form and questionnaire. To be eligible, participants needed to meet the following criteria: 1) aged 18 years or older, 2) diagnosed with major depressive disorder (MDD), 3) able to read and understand Chinese, and 4) clinically stable as judged by their psychiatrists. Based on previous studies (Lobana et al., 2001; Ma et al., 2020) , "clinically stable" is defined as a change in the dose of antidepressant medications that is less than 50% during the past three months based on a comparison between the highest and lowest antidepressant doses. The study protocol was centrally approved by the ethics committees of Beijing Anding Hospital and other participating hospitals.

Socio-demographic data collected using a pre-designed data collection sheet, included gender, age, place of residence, marital status, living with family or alone, employment status, health insurance, education level, perceived health status, subjective economic status, family history of psychiatric disorders, experience of cyberbullying, and history of suicide among family members or friends. Following previous studies (Li et al., 2017) , SI was assessed with a standard question ("Over the past year, have you thought that you would be better off dead?") that included a binary response option (yes/no). SP were assessed with a standard question ("Over the past year, have you made a plan for suicide?") featuring a binary response option (yes/no). SA were evaluated with a standard question ("Over the past year, have you attempted suicide?"), including a binary response option (yes/no). If a patient responded "yes" to any of the above three questions, he or she was defined as "having suicidality". Severity of residual depressive symptoms was measured using the validated Chinese version of the Patient Health Questionnaire-2 (PHQ-2) (Kroenke et al., 2003; Liu et al., 2016) . PHQ-2 total scores ranged from 0 to 6, with higher scores representing more severe depressive symptoms. Severity of fatigue was assessed using a single item fatigue numeric rating scale with options ranging J o u r n a l P r e -p r o o f Journal Pre-proof from "0" (no fatigue) to "10" (extreme fatigue) (Gladman et al., 2020) . Severity of physical pain was measured using a one-item Visual Analog Scale for Pain (VAS) (Hawker et al., 2011) with anchors of "0" (no pain at all) and "10" (worst pain imaginable). Finally, global quality of life (QOL) was measured with the first 2 items of the World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF):" How do you assess your quality of life?" and "Are you satisfied with your current health?" (Cheung et al., 2019; Skevington et al., 2004) . Higher scores reflected better QOL.

Data analyses were performed using SPSS version 25.0 (SPSS Inc., Chicago, Illinois, USA). Distributions of all continuous variables were checked for normality using P-P plots. Chi-square tests, independent samples t-tests, and

Mann-Whitney U tests were used, as appropriate, to compare MDD patients with suicidality versus those without suicidality in terms of sociodemographic and clinical variables. Analysis of covariance (ANCOVA) was used to compare QOL between patients with and without suicidality after adjusting for variables with significant group differences in univariate analyses. Binary logistic regression analyses with the "enter" method were used to examine independent correlates of suicide behaviors. SI, SP, and SA were entered as separate dependent variables while measures with significant suicidality versus no suicidality group differences in univariate analyses were independent variables after controlling for the impact of study site on responses. The level of significance level was set as p < 0.05 (two-tailed).

Altogether, 1,749 patients were invited to participate in the survey during the J o u r n a l P r e -p r o o f predefined study period. Of these, 1,718 met eligibility criteria and were included, generating a participation rate of 97.9%. Socio-demographic and clinical characteristics of participants are presented in Table 1 . The overall one-year prevalence of suicidality during the COVID-19 pandemic was 68.04% (95%CI = 65.84-70.25), with a SI prevalence of 66.4% (95%CI = 64.18%-68.65%), SP prevalence of 36.26% (95%CI = 33.99%-38.54%), and SA prevalence of 39.35% (95%CI = 37.04%-41.66%). Table 2 Table 2) .

ANCOVAs revealed that, even after controlling for significant correlates of suicidality in univariate analyses, significantly lower QOL scores were observed among MDD patients with SI (F (1, 1, 718) = 54.875, P<0.001), SP (F (1, 1, 718) = 54.849, P<0.001), and SA (F (1, 1, 718) = 55.037, P<0.001) compared to those without suicidality.

To the best of our knowledge, this was the first study to examine the one-year prevalence and correlates of suicidality in clinically stable patients with MDD during the COVID-19 pandemic. The overall one-year prevalence of suicidality during the COVID-19 pandemic was 68.04% (95%CI = 65.84-70.25%), with SI, SP and SA rates of 66.4% (95%CI = 64.18-68.65%), 36.26% (95%CI = 33.99-38.54%), and 39.35% (95%CI = 37.04-41.66%), respectively. Our prevalence findings were substantially higher than corresponding figures among MDD patients prior to the COVID-19 pandemic. For instance, previous studies found that the pre-pandemic one-year prevalence of SI, SP, and SA among MDD patients were 20.3% (Omary, 2020) , 14.4% (Lee et al., 2020) , and 2.7% (Hegerl et al., 2013) , respectively. A meta-analysis found that prevalence rates of SI, SP, and SA were 37.7% (95% CI = 32. In addition, the prevalence of SI in our sample was elevated compared to rates in a U.S. sample of veterans with pre-existing psychiatric conditions (19.2%) and a general population sample (16.4%) from China during the COVID-19 pandemic (Na et al., 2021; Shi et al., 2021) . It should be noted that the timeframes are different between studies; therefore, the direct comparisons should be made with caution.

J o u r n a l P r e -p r o o f As such, our findings underscore how the one-year suicidality rate in MDD patients is noticeably elevated during the COVID-19 pandemic even though respondents were clinically stable. There are several possible reasons for these elevations. First, some previously less stable patients may have experienced deteriorations in mental and/or physical health conditions as maintenance treatments were interrupted or discontinued due to insufficient access to hospital services during the pandemic . Second, to reduce the risk of COVID-19 infection, strict public health measures were adopted in many countries including China. Such lockdowns may have increased social isolation, loneliness, personal and economic losses, all of which could increase the risk of suicidality, particularly within at-risk groups such as MDD patients (Gunnell et al., 2020; Moutier, 2021; Reger et al., 2020) .

Female gender, younger age, and unmarried relationship status were associated with higher risk of suicidality among MDD patients in this study.

Gender differences exist in the psychopathology, prevalence and course of depression, behaviors of seeking help, and the response to treatment among MDD patients (Gagne, 2014; Picco, 2017) . Previous studies have implicated biological susceptibility (e.g., higher levels of inflammatory, neurotrophic, and serotonergic markers in women (Labaka et al., 2018) ), higher risk of sexual and physical abuse, lower self-esteem, more severe interpersonal violence, and exposure to stress associated with gender inequity as factors that contribute to higher risk of suicidality among women, at least with reference to attempts (Riecher-Rössler, 2017) . Compared with their older counterparts, younger MDD patients were also more likely to have suicidality, which aligns with previous findings indicating that younger people are more prone than older cohorts are to depression, anxiety, insomnia, acute stress, and suicidality related to attempts (Shi et al., 2020; Shi et al., 2021) . Furthermore, social isolation and lack of physical activity during the COVID-19 pandemic may increase the likelihood of suicidality in younger people (Shi et al., 2021; Vancampfort et al., 2018) .

Unmarried MDD patients were more likely to report suicidality during the COVID-19 pandemic, which is consistent with some (Fitzpatrick et al., 2020; Islam et al., 2021) but not studies (Na et al., 2021) . For instance, two studies found that unmarried persons reported higher suicidality compared to married peers (Fitzpatrick et al., 2020; Islam et al., 2021) . Conversely, among U.S. veterans with pre-existing psychiatric problems, marital status did not influence suicidality during the COVID-19 pandemic (Na et al., 2021) .

We found that urban residence, unemployment, and a having history of suicide among family members or friends were associated with higher risk of suicidality. MDD patients living in urban appeared more prone to having suicidality during the COVID-19 pandemic, which replicates the finding on the positive association between urban living and suicidality among Bangladeshi university students during the COVID-19 pandemic (Tasnim et al., 2020) .

Compared to those in rural areas, urban residents may experience more disruptions to daily life due to suspended public services such as public transportation, which may further worsen their psychiatric symptoms and increase the risk of suicidality. Unemployed patients were more likely to report suicidality, as a probable result of significant economic losses during the pandemic (Gunnell et al., 2020) and the deprivation of important psychosocial needs that employment provides ( (Zechmann and Paul, 2019) . The relationship between unemployment and increased suicidality have been well documented previously (Fergusson et al., 2007; Lee et al., 2018) . MDD patients who reported a history of suicide among family members or friends had higher risk of suicidality, which is consistent with previous findings On one hand, at risk MDD patients may have learned maladaptive responses to coping with stressors from observing responses of significant others (Nanayakkara et al., 2013; Tasnim et al., 2020) . Conversely, genetic susceptibility may also increase risk. even higher risk of suicidality (Hinduja and Patchin, 2010) . In this study, we found that MDD patients who were targets of cyberbullying were more likely to experience suicidality during the pandemic.

As expected, elevations in current fatigue, pain, and residual depressive symptoms were associated with higher risk of suicidality among MDD patients in this study; these data support the notion that more severe somatic symptoms and psychiatric problems increase risk of suicidality in MDD patients (Park et al., 2010; Zalpuri and Rothschild, 2016) . Recent findings also indicate that more severe psychiatric symptoms are linked to higher suicide risk in both the general population and those with pre-existing psychiatric conditions during the pandemic (Fitzpatrick et al., 2020; Na et al., 2021) . Residual psychiatric symptoms such as fatigue, pain, and depressive symptoms may be reflections of past suicidality or serve as prognosticators for worse outcomes, including increased risk for relapse, recurrence, and suicidality (Judd et al., 2000; Kennedy and Paykel, 2004) . Hence, these symptoms should be addressed in maintenance treatment and rehabilitation for clinically stable psychiatric patients during the pandemic.

In this study, MDD patients who had suicidality reported lower overall QOL scores compared to those who did not experience suicidality. Psychiatric patients J o u r n a l P r e -p r o o f with suicidality often have lower socioeconomic status (e.g., low income), poor social support, and more severe physical problems (Fergusson et al., 2007; Fitzpatrick et al., 2020; Lee et al., 2020; Na et al., 2021) . Therefore, it is reasonable to assume that patients with suicidality were more likely to have lower QOL in line with our results, which echo previous findings (Asrat et al., 2020; Li et al., 2017; Woo et al., 2014; Zhou et al., 2017) .

The strengths of this study included its large sample size, a multicenter study design from different regions of China that could increase the representativeness of the study sample, and the assessment of suicidal ideation, planning, and attempts, rather than a single index of suicidality during the COVID-19 pandemic.

However, its main limitations should be noted as well. First, due to the cross-sectional study design, causal relationships between suicidality and other variables (e.g., fatigue, pain, depression, QOL) could not be established. Second, for logistical reasons, participants were recruited based on a consecutive sampling, rather than a random sampling method, which may limit the generalizability of the findings. Third, this study focused on clinically stable MDD patients; therefore the findings could not be generalized to less clinically stable or remitted patients with MDD. Fourth, potentially important influences, such as the use of psychotropic medications and perceived social support, were not assessed in an effort to maintain reasonable response burdens for unpaid research volunteers. Fifth, because the study was initiated as a direct response to the COVID-19 pandemic, pre-pandemic rates of suicidality were not assessed and changes in rates as a result of the pandemic could not be assessed directly within the current sample. Future prospective studies should be conducted to facilitate comparisons of suicidality between different stages of the COVID-19 pandemic. Finally, although different sociocultural and economic contexts between study sites could bias results to an uncertain extent, study site was used as a covariate in multiple logistic regression analyses to control for related confounding effects.

In conclusion, this study found that suicidality is common among clinically stable MDD patients during the COVID-19 pandemic with notably higher rates than those from similar studies conducted prior to the pandemic. In addition, particular demographic factors and measures of distress severity were identified as predictors of suicidality. Together, these findings provide a comprehensive profile of suicidality in the MDD patients and highlight the importance of regularly screening for suicidality (e.g., at least once per month and in response to significant stressors in patients" lives) using relevant interviewer-rated or self-reported standardized questions and/or scales as well as the need for ongoing clinical care, even when MDD patients are clinically stable during the pandemic. Timely effective treatments are critical for those who experience suicidality during pandemics.

J o u r n a l P r e -p r o o f Zhou, Y., Cao, Z., Yang, M., Xi, X., Guo, Y., Fang, M., Cheng, L., Du, Y., 2017. Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder. Scientific Reports 7 (1), 1-8.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)

Risk factors for suicide in individuals with depression: a systematic review

Fast versus slow onset of depressive episodes: a clinical criterion for subtyping patients with major depression

Cyberbullying and Psychological Well-being in Young Adolescence: The Potential Protective Mediation Effects of Social Support from Family, Friends, and Teachers

Bullying, cyberbullying, and suicide

Depressive symptoms associated with COVID-19 preventive practice measures, daily activities in home quarantine and suicidal behaviors: Findings from a large-scale online survey in Bangladesh

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

Subjective quality of life and suicidal behavior among Taiwanese schizophrenia patients

Residual symptoms at remission from depression: impact on long-term outcome

The Patient Health Questionnaire-2: validity of a two-item depression screener

Biological sex differences in depression: a systematic review

Suicide rates, psychiatric hospital bed numbers, and unemployment rates from 1999 to 2015: a population-based study in Hong Kong

Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study

Major depressive disorder and suicide risk among adult outpatients at several general hospitals in a Chinese Han population

Progression of mental health services during the COVID-19 outbreak in China

PHQ-9 and PHQ-2 for Screening Depression in Chinese Rural Elderly

Quality of life in schizophrenia in India: comparison of three approaches

Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19

Suicide prevention in the COVID-19 era: transforming threat into opportunity

Prevalence, risk and protective factors associated with suicidal ideation during the COVID-19 pandemic in US military veterans with pre-existing psychiatric conditions

Depression and exposure to suicide predict suicide attempt

Absolute risk of suicide after first hospital contact in mental disorder

Predictors and Confounders of Suicidal Ideation and Suicide Attempts among Adults with and without Depression

Clinical characteristics of depressed patients with a history of suicide attempts: results from the CRESCEND study in South Korea

Gender differences in major depressive disorder: findings from the Singapore Mental Health Study

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

Suicide mortality and coronavirus disease 2019-a perfect storm

Sex and gender differences in mental disorders

Bullying involvement, psychological distress, and short sleep duration among adolescents

Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic

Prevalence and correlates of suicidal ideation among the general population in China during the COVID-19 pandemic

Suicide Risk and Prevention During the COVID-19 Pandemic: One Year On

The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group

Suicidal ideation among Bangladeshi university students early during the COVID-19 pandemic: Prevalence estimates and correlates. Children and youth services review 119

Suicidal ideation, deliberate self-harm behaviour and suicide attempts among adolescent outpatients with depressive mood disorders and comorbid axis I disorders

Physical activity and suicidal ideation: A systematic review and meta-analysis

Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study

World Health Organization

Does psychosis increase the risk of suicide in patients with major depression? A systematic review

Why do individuals suffer during unemployment? Analyzing the role of deprived psychological needs in a six-wave longitudinal study

The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: a systematic review and meta-analysis of observational studies

The COVID-19 pandemic is associated with an increased risk of mental health problems including suicide in many subpopulations, but its influence on stable patients with major depressive disorder (MDD) has been studied only rarely

Regular suicide screening and preventive measures on suicide should be provided to clinically stable MDD patients during the pandemic